NASDAQ: ADAP
Adaptimmune Therapeutics PLC Earnings Dates, Reports, Calls

Adaptimmune Therapeutics earnings were -$69.9M for the trailing 12 months ending Mar 31, 2025, with N/A growth year over year. The latest ADAP earnings report on Mar 31, 2025 announced Q1 2025 earnings of -$47.6M, down 35.9% from last quarter. For the last reported fiscal year 2024 ending Dec 31, 2024, ADAP reported annual earnings of -$70.8M, with -37.8% growth. The next ADAP earnings date is Aug 6, 2025.

ADAP earnings history

Current Revenue
$179.6M
Current Earnings
-$69.9M
Current Profit Margin
-38.9%

ADAP Return on Equity

Current Company
-185.5%
Current Industry
-60.2%
Current Market
31.3%
ADAP's Return on Equity (-185.5%)... subscribe to Premium to read more.
High Return on Equity Performance

ADAP undefined

Current Company
-26.8%
Current Industry
-2.5%
ADAP is generating lower Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

Be the first to know when ADAP announces earnings.

ADAP undefined

Current Company
-57.05%
Current Industry
5.8%
ADAP's ability to generate Return... subscribe to Premium to read more.
Increasing Return on Capital Employed Performance

ADAP vs Biotech Stocks

TickerEBITDAEarningsY/Y EarningsEPS
ADAP-$50.18M-$69.90MN/A-$0.24
VRCA-$55.56M-$65.99MN/A-$1.14
CNTBN/AN/AN/AN/A
PYXS-$94.25M-$95.23MN/A-$1.58
STRO-$205.86M-$245.22MN/A-$2.98

ADAP earnings dates

Next earnings date
Aug 6, 2025

Adaptimmune Therapeutics Earnings Reports & History FAQ

What were Adaptimmune Therapeutics's earnings last quarter?

On ADAP's earnings call on Invalid Date, Adaptimmune Therapeutics (NASDAQ: ADAP) reported Q1 2025 earnings per share (EPS) of -$0.18, up 0% year over year. Total ADAP earnings for the quarter were -$47.58 million. In the same quarter last year, Adaptimmune Therapeutics's earnings per share (EPS) was -$0.18.

If you're new to stock investing, here's how to buy Adaptimmune Therapeutics stock.

When does Adaptimmune Therapeutics report earnings?

The next ADAP earnings call is Invalid Date. Add ADAP to your watchlist to be reminded of Adaptimmune Therapeutics's next earnings date.

Is Adaptimmune Therapeutics profitable or losing money?

As of the last Adaptimmune Therapeutics earnings report, Adaptimmune Therapeutics is currently losing money. Adaptimmune Therapeutics's net profit (also called net income) for the twelve months ending Mar 31, 2025 was -$69.90 million, a 57.23% decrease year over year.

What was ADAP's earnings growth in the past year?

As of Adaptimmune Therapeutics's earnings date in Invalid Date, Adaptimmune Therapeutics's earnings has grown year over year. ADAP earnings in the past year totalled -$69.90 million.

What are Adaptimmune Therapeutics's earnings expectations?

The current EPS estimate for Adaptimmune Therapeutics's earnings report in Invalid Date is -$0.05.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.